Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies

In an interview with CancerNetwork^® during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, spotlighted the ongoing phase 1 AMPLIFY-201 trial (NCT04853017) assessing ELI-002 2P in patients with KRAS-mutant with solid tumors that were positive for minimal residual disease by circulating tumor DNA (ctDNA).

Transcript:

The abstract I presented this morning was [about a] trial in progress. It’s very important for [oncology professionals] to know about which trials are ongoing that could have a patient care impact. We had a very interesting trial of patients with minimal residual disease in solid tumors. Now that concept has made it in the mainstream more in leukemia and [other] hematologic malignancies, but it’s coming to the forefront in patients with solid tumor malignancies. What we are doing in this trial is [examining] patients with resected colon cancer even with resected liver metastases, pancreatic cancer, ovarian cancer, non–small cell lung cancer, or biliary tract cancers who have no evidence of disease. When we do a scan, there’s no evidence of disease; but when we take their blood sample for ctDNA, they’re positive. Then, they can get an experimental vaccine targeted against a KRAS mutation.

KRAS has long been called undruggable, but there are a lot of different small molecules and vaccine therapies that are trying to change the tide. I’m really excited about this trial [and there is] a lot of enthusiasm from other investigators. [It] is ongoing at our institution and multiple other institutions.

Reference

Pant S, Furqan M, Muhsin R, et al. First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. J Clin Oncol. 2022;40(suppl 16):TPS2701. doi:10.1200/JCO.2022.40.16_suppl.TPS2701